End-of-day quote
Korea S.E.
23:00:00 27/06/2024 BST
|
5-day change
|
1st Jan Change
|
4,800
KRW
|
-0.10%
|
|
-1.84%
|
-15.79%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
118,505
|
137,624
|
142,830
|
117,712
|
100,392
|
87,364
|
Enterprise Value (EV)
1 |
115,561
|
125,219
|
133,016
|
101,565
|
99,285
|
102,864
|
P/E ratio
|
59.3
x
|
8.48
x
|
11.1
x
|
23.5
x
|
12.3
x
|
54.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.24
x
|
1.19
x
|
1.14
x
|
0.84
x
|
0.6
x
|
0.47
x
|
EV / Revenue
|
1.21
x
|
1.08
x
|
1.07
x
|
0.72
x
|
0.59
x
|
0.55
x
|
EV / EBITDA
|
13.4
x
|
8.79
x
|
10.5
x
|
13.7
x
|
7.65
x
|
13.1
x
|
EV / FCF
|
-5.35
x
|
18.3
x
|
-17.4
x
|
38.4
x
|
-5.93
x
|
-5.18
x
|
FCF Yield
|
-18.7%
|
5.47%
|
-5.74%
|
2.61%
|
-16.9%
|
-19.3%
|
Price to Book
|
1.91
x
|
1.9
x
|
1.71
x
|
1.42
x
|
1.11
x
|
0.96
x
|
Nbr of stocks (in thousands)
|
15,113
|
15,373
|
15,469
|
15,327
|
15,327
|
15,327
|
Reference price
2 |
7,841
|
8,952
|
9,233
|
7,680
|
6,550
|
5,700
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
95,338
|
115,793
|
124,809
|
140,157
|
167,737
|
187,155
|
EBITDA
1 |
8,595
|
14,251
|
12,629
|
7,400
|
12,977
|
7,844
|
EBIT
1 |
7,367
|
12,538
|
10,599
|
4,794
|
9,864
|
3,073
|
Operating Margin
|
7.73%
|
10.83%
|
8.49%
|
3.42%
|
5.88%
|
1.64%
|
Earnings before Tax (EBT)
1 |
2,078
|
12,151
|
9,728
|
5,605
|
8,391
|
3,476
|
Net income
1 |
1,218
|
10,031
|
8,372
|
4,930
|
8,034
|
3,061
|
Net margin
|
1.28%
|
8.66%
|
6.71%
|
3.52%
|
4.79%
|
1.64%
|
EPS
2 |
132.2
|
1,055
|
831.0
|
326.9
|
532.0
|
104.0
|
Free Cash Flow
1 |
-21,618
|
6,847
|
-7,641
|
2,647
|
-16,738
|
-19,870
|
FCF margin
|
-22.68%
|
5.91%
|
-6.12%
|
1.89%
|
-9.98%
|
-10.62%
|
FCF Conversion (EBITDA)
|
-
|
48.05%
|
-
|
35.76%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
68.26%
|
-
|
53.69%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
15,499
|
Net Cash position
1 |
2,944
|
12,405
|
9,814
|
16,146
|
1,107
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
1.976
x
|
Free Cash Flow
1 |
-21,618
|
6,847
|
-7,641
|
2,647
|
-16,738
|
-19,870
|
ROE (net income / shareholders' equity)
|
2.99%
|
15.1%
|
11.2%
|
6.21%
|
9.47%
|
3.45%
|
ROA (Net income/ Total Assets)
|
5.47%
|
6.83%
|
5.78%
|
2.59%
|
4.49%
|
1.17%
|
Assets
1 |
22,258
|
146,776
|
144,730
|
190,320
|
178,933
|
260,637
|
Book Value Per Share
2 |
4,106
|
4,723
|
5,400
|
5,404
|
5,898
|
5,933
|
Cash Flow per Share
2 |
155.0
|
798.0
|
383.0
|
634.0
|
1,558
|
1,270
|
Capex
1 |
17,454
|
2,646
|
9,389
|
5,268
|
18,974
|
23,385
|
Capex / Sales
|
18.31%
|
2.28%
|
7.52%
|
3.76%
|
11.31%
|
12.49%
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
|
1st Jan change
|
Capi.
|
---|
| -15.79% | 53.39M | | +19.91% | 43.77B | | +30.16% | 22.83B | | +20.25% | 15.56B | | +18.74% | 14.34B | | +54.18% | 12.96B | | -0.05% | 6.79B | | -11.72% | 6.41B | | -8.87% | 5.73B | | +14.65% | 5.69B |
Generic Pharmaceuticals
|